Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Study to Investigate the Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccines MRT5421, MRT5424, and MRT5429 in Healthy Participants Aged 18 Years and Above

NCT06361875 is registered in ClinicalTrials.gov with Sanofi Pasteur, a Sanofi Company as lead sponsor.

NCT NCT06361875
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06361875 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Study to Investigate the Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccines MRT5421, MRT5424, and MRT5429 in Healthy Participants Aged 18 Years and Above
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Phase
Phase 1/2
Overall status
Completed
Start date
April 1, 2024
Completion date
June 9, 2025
Enrollment
908 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

healthy volunteers, influenza immunization